New nasal spray for allergies passes first safety check

NCT ID NCT07345442

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial tested the safety and tolerability of a new corticosteroid nasal spray called PA9159 in 36 healthy Chinese adults. Participants received either a single dose or seven daily doses of the spray, or a placebo. The goal was to find the maximum safe dose and see how the drug moves through the body. This is a first step toward possibly treating allergic rhinitis.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
PA9159 (a novel corticosteroid) nasal spray
What this could lead to
If successful, this could lead to a new treatment option for allergic rhinitis symptoms.
What could go wrong
This is a very early Phase 1 safety study with only 36 healthy people, not patients. It does not test effectiveness, and the drug may not work or may have side effects in later trials.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ALLERGIC RHINITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

allergic rhinitis Rhinitis, Allergic

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • The First Affiliated Hospital of Nanchang University

    Nanchang, Jiangxi, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.